Innovative Diagnostic Oncology Solutions
Here at Signature Oncology, we are focused on the development of new cancer diagnostic tests, which are based on an innovative technology platform in melanoma that empowers clinician decision making and advances patient care and treatment. We are proud of what we do here, so feel free to contact our team today to learn more.
Our Board
Dr Thomas Duthy Ph.D MBA MAICD
Chairman and Co-Founder
Dr Duthy has over 19 years of direct financial markets experience having worked in sell-side equity research, and senior executive roles across investor relations and corporate development, along with a number of Executive and Non-Executive ASX Board appointments. Dr Duthy is the Founder and CEO of Nemean Group Pty Ltd, a boutique corporate advisory and investor relations firm specialising in delivering value-added services across the life sciences, medical devices, healthcare, technology and emerging company sectors. Transactions have included the A$100 million cash sale of the Ellex Medical (ASX:EYE) ophthalmic laser business to Lumibird in 2020 and the A$111 million cash acquisition of Limeade (ASX:LME) by WebMD Health Services in 2023. Prior to establishing Nemean Group in October 2018, Dr Duthy was the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (ASX:SRX), which was sold to CDH Investments in September 2018 for A$1.9 billion and remains the largest medical device transaction in Australian corporate history. Prior to Sirtex, Tom spent ten years as a leading sell-side healthcare and biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies. Dr Duthy is an Executive Director of Invex Therapeutics Limited (ASX:IXC) and Neurotech International (ASX:NTI) and Chairman of Arovella Therapeutics (ASX:ALA).
TBA
Incoming CEO & Managing Director
Mr David McAuliffe B.Pharm LLB (Hons.)
Director and Co-Founder
Mr McAuliffe is an experienced company director and entrepreneur who has had over twenty years’ experience, mostly in the international biotechnology field. During that time, he was involved in numerous capital raisings and in-licensing of technologies.
He is a founder of several companies in Australia, France and the United Kingdom, many of which have become public companies. Mr McAuliffe has an Honours degree in Law, a Bachelor of Pharmacy degree and is the President of the Dyslexia – Speld Foundation WA (Inc). Mr McAuliffe is a Non-Executive Director of Invex Therapeutics Limited (ASX:IXC).
Dr Jason Loveridge Ph.D
Co-Founder
Dr Loveridge is a founder of Invex Therapeutics Limited (ASX:IXC) and also CEO of 4SC AG, a German publicly listed oncology company. He has more than 30 years of international experience across Europe, Asia and the US in senior management positions in life sciences companies and as an investment professional dealing in both privately held and publicly traded companies. Additionally, he has substantial transactional experience in the sale and partnering of biotechnology assets.
Dr Loveridge graduated in Biochemistry and Microbiology from the University of New South Wales, Australia, and holds a Ph.D. in Biochemistry from the University of Adelaide, Australia. He is also a fellow of the Royal Society of Medicine. Dr Loveridge is Non-Executive Chairman of Invex Therapeutics (ASX:IXC).
Professor Christian Blank M.D Ph.D MBA
Co-Founder
Professor Blank is the Inventor and developer of the core Signature Oncology Intellectual property. Professor Blank is group leader and clinical staff member at the Netherlands Cancer Institute, Antoni Van Leewenhoek (NKI-AVL) and Professor at the University of Regensburg. He is a member of several prestigious societies, including ESMO and ASCO. Dr Blank has been an invited speaker at more than 100 national and international congresses and is the author of more than 330 publications. His research interests broadly include neoadjuvant immunotherapies, targeted and biological response modifiers, and prognostic markers for cancer immunotherapies. Professor Blank pioneered neoadjuvant immune checkpoint inhibition in melanoma. He holds advisor roles with a number of leading pharmaceutical companies including BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, and Pierre Fabre.
Our Governance
Signature Oncology Board and management maintain high standards of corporate governance as part of their commitment to maximise shareholder value.
The Company is committed to implementation of ASX Corporate Governance Council’s revised Corporate Governance Principles and Recommendations. In addition, the board and management are committed to continuing to review the company’s corporate governance practices as we continue to grow our business and mature as an organisation.
